The Future of Targeted Therapy for Leiomyosarcoma

Ryan A. Denu, Amanda M. Dann, Emily Z. Keung, Michael S Nakazawa, Elise F. Nassif Haddad

Research output: Contribution to journalReview articlepeer-review

Abstract

Leiomyosarcoma (LMS) is an aggressive subtype of soft tissue sarcoma that arises from smooth muscle cells, most commonly in the uterus and retroperitoneum. LMS is a heterogeneous disease with diverse clinical and molecular characteristics that have yet to be fully understood. Molecular profiling has uncovered possible targets amenable to treatment, though this has yet to translate into approved targeted therapies in LMS. This review will explore historic and recent findings from molecular profiling, highlight promising avenues of current investigation, and suggest possible future strategies to move toward the goal of molecularly matched treatment of LMS. We focus on targeting the DNA damage response, the macrophage-rich micro-environment, the PI3K/mTOR pathway, epigenetic regulators, and telomere biology.

Original languageEnglish (US)
Article number938
JournalCancers
Volume16
Issue number5
DOIs
StatePublished - Mar 2024

Keywords

  • genomics
  • immunotherapy
  • leiomyosarcoma
  • precision oncology
  • targeted therapy
  • transcriptomics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'The Future of Targeted Therapy for Leiomyosarcoma'. Together they form a unique fingerprint.

Cite this